This press release may not be made public, published or distributed, directly or indirectly, in or into the United States of America, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such disclosure, distribution or publication of this press release would be unlawful or require additional registration measure- or other measures. For more information, refer to the section "Important information" at the end of this press release.

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

GOTHENBURG, Sweden, 13 March 2026 – Isofol Medical AB ("Isofol" or the "Company") carried out a rights issue of units in June/July 2025. In connection with the rights issue, Isofol issued a total of 39,863,928 warrants of series TO1. One (1) warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO1 corresponds to seventy (70) percent of the volume-weighted average price of the Company's share on Nasdaq Stockholm during the period from and including 2 March 2026 up to and including 13 March 2026. During the measurement period, the volume-weighted average price of the Company's share amounted to approximately SEK 0.69; consequently, the exercise price for the warrants of series TO1 has been set at SEK 0.48. The exercise period for the warrants of series TO1 runs from and including 16 March 2026 up to and including 30 March 2026. Isofol has previously announced that the Company has received a top guarantee commitment from Solasia Pharma K.K. and letters of intent from existing shareholders, together representing approximately 42 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants.

Summary of terms and conditions for the warrants

Exercise period
16 March 2026 – 30 March 2026

Issue volume
39,863,928 warrants of series TO1, entitling holders to subscribe for 39,863,928 shares. If all warrants are exercised, the Company will receive approximately MSEK 19.1 before issue costs.

Exercise price
SEK 0.48 per share

Last day of trading in warrants of series TO1
26 March 2026

Share capital and dilution
If all warrants of series TO1 are exercised in full for subscription of new shares, the total number of shares in the Company will increase by 39,863,928 shares, from 281,107,224 shares to 320,971,152 shares, and the share capital will increase by SEK 1,220,546.915745, from SEK 8,606,892.809164 to SEK 9,827,439.724914, corresponding to a dilution effect of approximately 12.42 percent of the total number of shares in the Company

Please note that warrants not exercised for subscription of shares by 30 March 2026, or sold by 26 March 2026, will expire without value. To prevent the warrants from expiring, holders must actively subscribe for shares or sell the warrants.

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States of America, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such disclosure, distribution or publication of this press release would be unlawful or require additional registration measure- or other measures. For more information, refer to the section "Important information" at the end of this press release.

Top guarantee commitment

In connection with the exercise period for the series TO1 warrants, the Company has entered into atop guarantee agreement free of charge with an existing shareholder, the Company's Japanese development and commercialisation partner Solasia Pharma K.K. (the "Guarantor"). The top guarantee entails that the Guarantor has committed to guarantee approximately 5.3 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants, corresponding to approximately 1.0 MSEK. In the event the top guarantee is called upon, in whole or in part, the Guarantor will subscribe for shares through a directed new share issue at a subscription price corresponding to the exercise price of the series TO1 warrants, i.e. 0.48 SEK per share. The guarantee commitment has been agreed in writing but has not been secured by way of bank guarantee, blocked funds, pledge or similar arrangement, and accordingly there is a risk that the guarantee commitment may not be fulfilled. In the event the Guarantor's top guarantee is utilised, the board of directors of Isofol intends to exercise the authorisation granted at the Annual General Meeting on 21 May 2025 and resolve on a directed new share issue on the same terms as applicable to the exercise of TO1.

Letters of intent

In addition, a number of Isofol's larger existing shareholders have submitted letters of intent to exercise their respective series TO1 warrants in accordance with their pro rata holdings. The same applies to the Company's board of directors and management. In aggregate, these letters of intent represent approximately 36 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants. The letters of intent do not constitute binding commitments and accordingly there is a risk that they may not be fulfilled.

In aggregate, the top guarantee commitment and letters of intent represent approximately 42 percent of the proceeds that may be raised by the Company upon full exercise of the series TO1 warrants. Both the top guarantee and the letters of intent have been provided without compensation.

Now to exercise the warrants

Nominee-registered warrants (custody account)

Subscription and payment through exercise of warrants shall be carried out in accordance with instructions from the respective nominee. Please note that certain banks may, for administrative reasons, have an earlier deadline for exercise than 30 March. Please contact your nominee for further information.

Directly registered warrants (VP account)

No issue statement or payment instructions will be distributed. Subscription shall be made through simultaneous cash payment in accordance with the instructions on the application form. The warrants will thereafter be replaced with interim shares pending registration with the Swedish Companies Registration Office (Bolagsverket).

An application form with payment instructions will be available on the Company's website, www.isofolmedical.com.

Outcome and delivery of new shares

The outcome of the warrant exercise will be announced through a press release around 1 April 2026. Subscribed and paid shares may be registered in the subscriber's securities account as interim shares until the issue has been registered with the Swedish Companies Registration Office, upon which the interim shares will automatically be converted into shares in Isofol.

Complete terms and conditions

Complete terms and conditions for the warrants are available on the Company's website, www.isofolmedical.com.

Advisors

ABG Sundal Collier AB is acting as financial advisor to the Company, Advokatfirman Vinge KB is legal advisor, to the Company and Aqurat Fondkommission is the issuing agent in connection with the administration of TO1.

For more information, please contact

Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

Margareta Hagman, Chief Financial Officer
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0) 738 73 34 18

The information was submitted for publication, through the agency of the contact persons set out above, on 13 March 2026 at 18:40 CET.

About Isofol

Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com

Important information

The information in this press release does not contain and does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities in Isofol. No action has been taken, and no actions will be taken, to permit an offer to the public in any jurisdictions other than Sweden.

This release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Isofol. In order for investors to fully understand the potential risks and benefits associated with a decision to exercise warrants, any investment decision should only be made based on the information in the prospectus published by the Company on 17 June 2025 ("**Prospectus**"). Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an **advertisement**.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction in which such action would be unlawful or would be subject to legal restrictions or require any

other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares, warrants or other securities in Isofol have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended (the "**Securities Act**") or the securities legislation of any state or other jurisdiction in the United States of America and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States.

Within the European Economic Area ("**EEA**"), no public offering of shares, warrants or other securities ("**Securities**") is made in other countries than Sweden. In other member states of the European Union ("**EU**"), such an offering of Securities may only be made in accordance with the exceptions in the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "**relevant persons**"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "*intend*", "*will*", "*assess*", "*expect*", "*may*", "*plan*", "*consider*", "*estimate*" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development, and the actual outcome could differ materially from the forward-looking statements.

This information, opinions and forward-looking statements contained in this press release applies only as of the date hereof and may be subject to change without notice. Isofol makes no commitment to publicly update or revise any forward-looking statements, future events or similar circumstances other than as required by applicable law.

Since Isofol conducts essential services according to the Swedish Screening of Foreign Direct Investments Act (Sw. *lag (2023:560) om granskning av utländska direktinvesteringar*), certain

investments in the Company's shares may require review by the Inspectorate of Strategic Products (ISP). More information on this can be found on the Company's website, https://isofolmedical.com.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.